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ABSTRACT 
 
DEVELOPING A MURINE MODEL FOR Q FEVER 
 
Coxiella burnetii is a gram-negative, intracellular bacterium that causes 
disease in humans and animals. The bacterium is commonly found in nature and 
humans and animals develop infections by inhaling infectious aerosols. Animal 
infections are generally asymptomatic, but the organism can induce abortion in 
pregnant sheep, goats, and cattle. Human infections, called Q fever, can induce 
mild to moderate disease, and lifelong infections may develop. Research to 
characterize this bacterium has been difficult due to its intracellular nature, and 
studying experimental infections in animal models has provided important 
information about the bacterial lifecycle and pathogenesis of the disease. The 
studies described here focused on evaluating a number of facets of C. burnetii 
infection in C57BL/6 inbred mice. Infections were determined through 
immunofluorescence detection, quantitative PCR assays, and histopathologic 
analysis. Mice developed similar histopathologic lesions as humans, specifically 
hepatitis, interstitial pneumonia, and myocarditis when infected by intranasal 
inoculation with the Nine Mile phase I strain of the bacterium. Detection of 
bacterial DNA in tissues and frequency of histopathologic lesions were highest 
two weeks after infection, with a significant decrease observed 42 and 59 days
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after infection. Mouse age and chemically induced immunosuppression with 
dexamethasone or cyclophosphamide were evaluated in C. burnetii infected mice 
to determine if these factors exacerbated disease. These studies revealed that 
neither age, (nine-weeks versus nine-months), or chemically induced 
immunosuppression (dexamethasone versus cyclophosphamide) significantly 
enhanced disease manifestations in infected mice. Additionally, antimicrobial 
treatment with doxycycline was evaluated in treating C. burnetii infections in 
mice. Such treatment reduced splenic pathology but did not significantly reduce 
the frequency of other histopathologic lesions or the amount of bacterial DNA 
detected in tissues. Overall, C57BL/6 mice infected by intranasal inoculation 
develop histopathologic lesions similar in many respects to what is observed in 
infected humans. However, disease manifestations were not exacerbated by host 
age or the immunosuppressive treatments investigated. Additionally, the dose of 
doxycycline received by mice was only marginally effective in treating bacterial 
infection in mice.
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CHAPTER 1: LITERATURE REVIEW 
History of Coxiella burnetii 
Coxiella burnetii was discovered during a public health review of an illness 
plaguing slaughterhouse workers in Brisbane, Australia from 1933 to 1935 [1]. 
The most common symptom was fever, which lasted from seven to 24 days. Dr. 
Edward Derrick was the first person to determine that the febrile illness was 
caused by a novel infectious organism and gave the disease the name Q fever. 
Subsequently, he was able to illicit a febrile response in guinea pigs when he 
inoculated them with blood and urine from infected patients; however he was 
unable to isolate or identify the infectious organism [1]. He sent infected guinea 
pig liver samples to virologist Dr. Francis Macfarlane Burnet who was able to 
reproduce the febrile illness in mice and observed rickettsia-like particles in 
infected mouse spleens [2]. Dr. Burnet along with Dr. Mavis Freeman infected 
several animal species to determine the pathogenesis and virulence of the 
organism in different hosts. They determined that the guinea pig liver emulsion 
was infective for mice and monkeys, the organism was filterable, and the 
pathogen survived in the chorio-allantois of developing eggs without inducing 
lesions [2].  
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In 1938, Dr. Herald Cox isolated a similar small, pleomorphic; gram-negative 
pathogen from Dermacentor andersoni ticks near Nine Mile Creek, Montana and 
named it Rickettsia diaporica [3-5]. The Australian and D. andersoni isolates 
were compared for virulence and infectivity and determined to be the same 
species. Cox re-named the pathogen Rickettsia burnetii after discoveries made 
by Dr. Burnet. Dr. Cornelius Philip solicited that the pathogen be placed in a new 
genus, Coxiella, to honor Dr. Cox’s discovery [6]. Coxiella burnetii was classified 
into the Proteobacteria phylum, alpha-1 class, Rickettsiales order, Rickettsiaceae 
family, in the Rickettsia tribe [7]. The pathogen was evaluated in a variety of 
comparison studies to other rickettsial organisms, specifically Rickettsia 
prowazeki, and did not have the same characteristics. Based on the comparison 
of 16S ribosomal RNA gene sequences, Coxiella burnetii was reclassified and 
remained in the Proteobacteria phylum, but was placed in the 
Gammaproteobacteria class, Legionellales order, in the Coxiellaceae family [8]. 
Coxiella burnetii’s closest phylogenetic neighbors are Legionella and Francisella 
[8]. Legionella pneumophila is the closest related pathogen due to its genetic and 
phenotypic characteristics, specifically the fact that the bacterium undergoes 
intracellular growth within a membrane bound vacuole [8].  
Bacteriology 
 
C. burnetii is a small, pleomorphic, intracellular bacterium measuring 0.2 
by 0.7 micrometers [9]. Much variability has been observed when the organism 
undergoes Gram-staining; however, electron microscopy has shown that the 
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outer membrane of the bacterium has characteristics typical of gram-negative 
bacteria [9, 10].  
The complete genome of C. burnetii Nine Mile strain was sequenced by 
Seshadri et al. in 2003 [11]. C. burnetii has a single, circular chromosome two 
mega base pairs in length [12]. The Nine Mile strain is 1,995, 275 base pairs long 
and has a molecular G+C content of 42.6% [11, 13]. This strain harbors one 34.7 
kilo base plasmid, QpH1, while other plasmids have been identified in other 
strains including, QpDG, QpDV, and QpRS, which allows for genetic typing 
between strains [13-16]. Plasmid type has been proposed to be related to 
virulence and disease severity in humans [14]. Insertion elements (IS) were 
commonly observed in the Nine Mile genome, with approximately 20 copies of 
the IS1111 gene; the IS is not located in the QpH1 plasmid [11]. Additionally, the 
C. burnetii genome has components of type I, II, and IV secretion systems; the 
type IV secretion system is similar to the one observed in the Legionella genome 
[17, 18]. 
Davis and Cox were the first researchers to observe that the bacterium 
was distinctly pleomorphic [3]. In 1959, Dr. Nonna Kordova discovered that there 
was antigenic variability among the bacterium [19]. These findings led to 
additional studies evaluating the differences in the two bacterial life forms and the 
idea of a biphasic developmental cycle [20, 21]. In 1981, researchers McCaul 
and Williams proposed that C. burnetii had a biphasic developmental life cycle, 
which included a small, metabolically inert small cell variant (SCV) and a large, 
metabolically active large cell variant (LCV) [3, 10, 22]. The researchers 
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observed another cell variant in electron microscopy studies and identified it as a 
spore-like particle (SLP) [8, 23].  
Small cell variants are rod shaped, have electron-dense condensed 
chromatin, and are 0.2 to 0.5 um long. LCVs are pleomorphic with dispersed 
chromatin, measuring greater than 1 um in length, and are metabolically active in 
vitro [10, 22]. The cell variants have contrasting structural components and 
resistance mechanisms [13, 23]. Unlike the fragile LCV, the SCV is resistant to 
lysis by pressure and other physical disruptions while retaining its morphologic 
features [23, 24]. During infection, SCVs are phagocytosed by eukaryotic cells, 
pulmonary macrophages and Kupffer cells, and sequestered in phagolysosomes. 
The acidic environment of the phagolysosome activates the transition from SCVs 
to metabolically active LCVs. The LCVs are able to transition back prior to lysis of 
the phagolysosome, resulting in the release of SCVs [22, 23]. McCaul and 
Williams proposed that the spore-like form is induced by eukaryotic cell changes 
during LCV replication, which leads to the development and release of spore-like 
particles [10]. The SLP form of the bacterium has not been fully elucidated since 
its discovery in 1981. Recently, it was theorized that SLPs differentiate to SCVs 
[13, 25]. However, these particles have not been isolated or purified to prove 
such hypotheses. Additionally, the endospore form is only occasionally observed 
and the C. burnetii genome lacks known sporulation genes [10, 11, 22]. The SCV 
has shown resistance to biochemical and physical agents, suggesting this variant 
replaces the need for a SLP [24, 26]. Definitive information is not available about 
the existence of a SLP C. burnetii variant in the developmental lifecycle. 
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However, research has proven that a biphasic developmental cycle exists for C. 
burnetii and the different resistance mechanisms and metabolic activities of the 
variants are essential for bacterial survival in the host.  
Bacteria enter into host cells through the process of microfilament 
endocytosis in which the host cell, upon binding the bacterium, induces 
reorganization of the actin cytoskeleton leading to membrane protrusions at the 
site of bacterial attachment [27-30]. C. burnetii entry into host cells ends in the 
pathogen residing in a parasitophorous vacuole (PV) resembling a secondary 
lysosome [8, 13]. The PV is acidic, pH 4.7- 4.8, and the acidic nature of this 
vacuole activates C. burnetii SCVs to transform to LCVs [13, 31]. The C. burnetii 
growth cycle has been defined in cell culture and includes lag, log, and stationary 
phases [18]. In Vero cell culture, Coleman et al., observed a lag phase beginning 
two days post infection, with no increase in bacterial replication, characterized by 
SCVs transitioning to LCVs. This was followed by exponential growth in the PV 
dominated by LCVs four days after infection. Finally, the LCV transitions back to 
a SCV during a stationary phase that starts six days after infection just before cell 
lysis, which allows SCVs to infect other cells [18]. A similar system is believed to 
occur in the mammalian host, with SCVs infecting alveolar macrophages during 
inhalation of infectious organisms [24, 32].  
In addition to the biphasic developmental cycle, C. burnetii has two phase 
variations, phase I and II, based on the lipopolysaccharide (LPS) structure [33]. 
These forms are indistinguishable under a microscope but have distinct virulence 
attributes [13]. Phase I is characterized by a full-length, smooth-type LPS and is 
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the more virulent form, while the phase II form has a truncated, rough-type LPS 
and is the avirulent form [33]. Phase II LPS lacks sugar groups virenose and 
dihydrodroxystreptose observed in phase I [34]. The antigenic change from the 
virulent to the avirulent form is often the result of a chromosomal deletion, 
affecting the biosynthetic genes in the O-antigen cluster of the LPS and genes 
involved in virenose synthesis [35, 36]. The LPS is theorized to be antigenic for 
C. burnetii and has been found to induce production of inflammatory cytokines in 
human and murine macrophages and stimulates antibody production [37, 38]. 
Phase I cells are not as readily ingested by host cells as phase II forms. Phase I 
requires αvβ3 integrin on host cells whereas phase II cells require αvβ3 integrin 
and CR3 on the host cell for entry [39]. Phase I cells can be isolated from 
infected hosts but phase II cells cannot [13]; the only time phase II cells can be 
obtained is following serial passages in tissue culture or eggs [40]. Phase I cells 
have several ways to evade identification by the host innate immune system, 
leading to phagocytosis of the organism. Virulent phase I organisms stimulate the 
activation of two src-related protein tyrosine kinases, Lyn and Hck, resulting in 
actin cytoskeletal rearrangement and impairment of phagocytosis by the host cell 
[27, 30]. Antibodies to surface proteins on C. burnetii are sterically inhibited to 
bind phase I organisms [41]. Phase I LPS masks Toll-like receptor (TLR) ligands 
to prevent host dendritic cells from binding, and inhibits CR3 interaction with host 
cells to prevent efficient binding, evading phagocytosis by the host cell [42]. 
Additionally, membrane ruffling induced by endocytosis blocks binding of phase I 
cells to CR3 on the host cell, decreasing efficiency of internalization [27]. 
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Contrastingly, avirulent phase II organisms cannot prevent phagosome-lysosome 
fusion resulting in phagocytosis of the organism [43]. Phase II organisms have a 
lower carbohydrate content due to the truncation in their LPS, making the cell 
highly hydrophobic, which increases interactions with the receptors on the host 
cell plasma membrane [32]. The phase I cells are more virulent in the host due to 
their ability to evade identification and subsequent phagocytosis by host cells.   
Epidemiology  
 
 C. burnetii  is a ubiquitous environmental pathogen that has been reported 
throughout the U.S. [44] and in nearly every country except for New Zealand and 
the Antarctic [13, 45]. The bacterium is able to infect a wide range of reservoirs 
including, domestic and wild mammals, birds, and arthropods [13, 46]. Cattle, 
sheep, and goats are the primary reservoir hosts and are responsible for the 
majority of human infections [47]. The primary mode of transmission for humans 
and animals is inhalation of infectious organisms; the infectious dose for humans 
has been found to be fewer than 10 bacteria [48, 49]. Ingestion of infectious 
organisms and the bite of infected ticks are also routes of infection [32, 46, 50]. 
Several studies have determined arthropod reservoirs, particularly tick species, 
to be important in the spread of the bacteria but not essential in the bacterial 
lifecycle [47, 51]. The bacterium targets the reproductive organs of reservoir 
hosts, specifically the placenta, uterus, and mammary glands; infected placentas 
harboring greater than 109 microorganisms per gram of tissue have been 
documented [52-54]. Bacterial transmission primarily occurs during parturition 
when infected placental tissue and birthing contents become aerosolized [48, 55-
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57]. Bacteria are also excreted in small amounts in the urine, feces, and milk of 
infected parturient reservoir hosts, and have been found in vaginal mucus of non-
pregnant and pregnant ewes, representing additional modes of bacterial 
transmission [58, 59]. The bacterium can survive in the environment for long 
periods of time and infectious aerosols have been found two weeks after 
parturition [47]. Also, previous studies by Welsh et al. indicated that C. burnetii 
could survive in the soil for up to 150 days [57]. Research by Kersh et al. 
evaluated the presence of C. burnetii in environmental samples throughout the 
United States between 2006 and 2008 [44]. Kersh found that C. burnetii was 
found in a broad variety of environments, especially public locations (banks, 
schools, post offices) with no surrounding farms, ranches, or livestock [44]. The 
ability of the bacterium to survive in the environment for long periods of time, 
infect several reservoir hosts, and become aerosolized allows C. burnetii to 
contaminate or infect a wide range of habitats and species, which makes it a 
successful pathogen.  
Human Disease 
  
Humans primarily become infected through the inhalation of infectious 
aerosols [48]. Several studies have attempted to determine the risks associated 
with C. burnetii contaminated dairy products. However, results to these studies 
are contradictory and the risk of infection by that route for humans remains 
inconclusive [25, 46, 60]. While infected ticks are important in the natural 
transmission cycle, they apparently do not transmit C. burnetii to humans [25, 
50]. Human to human transmission is rare, but has been observed in cases of 
 
 
9
sexual transmission [61, 62] and perinatal infections [63]. Human disease can be 
classified as either acute or chronic. Approximately 60% of infected people 
develop asymptomatic infection [25, 64]. Flu-like symptoms, fever, and severe 
headaches are clinical symptoms associated with acute disease, and pneumonia 
and hepatitis are common histopathologic lesions associated with acute infection 
[1, 65, 66]. Chronic disease develops in approximately 1-2% of acutely infected 
cases; symptoms may not develop until years after infection [64]. Chronic 
disease is often associated with culture-negative endocarditis, and rarely, 
osteomyelitis, osteoarthritis and Q fever fatigue syndrome [64, 67, 68]. 
Development of certain disease manifestations associated with C. burnetii 
infection have been linked to the phase and strain of the pathogen, the 
inoculation route, the dose received [14, 69], and host factors [70, 71]. 
Observational research by Dr. Thomas Marrie demonstrated that inhalation of 
infectious organisms induced pneumonia while intraperitoneal inoculation and 
ingestion of infectious organisms resulted in hepatitis [69]. Pathologies 
associated with C. burnetii infection have also been geographically linked. Q 
fever pneumonia is frequently observed in Canada and Spain while Q fever 
hepatitis is commonly observed in France and Australia [72]. Hepatitis is 
currently the most common presentation of acute Q fever worldwide [25], and 
can present as clinically asymptomatic and granulomatous hepatitis [25]. Atypical 
pneumonia is the second most frequently observed lesion associated with C. 
burnetii infection [25]. Pulmonary lesions are usually mild; however, the duration 
of symptoms can last from 10 to 90 days [66]. The most commonly observed 
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chronic disease manifestation associated with chronic Q fever is endocarditis, 
which may appear with pericardial effusion and/or pericarditis [25, 73, 74]. This 
lesion is almost exclusively seen in patients with pre-existing valvulopathies [46, 
68, 74].  
The limited understanding of the disease pathogenesis in humans is due 
in part to the difficulties associated with characterizing an intracellular pathogen 
and lack of available animal models developing similar disease to humans. 
Although little information is available on disease pathogenesis in humans, 
previous research has uncovered immune components necessary in preventing 
and clearing bacterial infection. Cell mediated immunity is essential in controlling 
Q fever, and deficiencies in this function result in chronic disease [13, 25, 75]. 
Previous research has determined that chronically infected people lack sufficient 
T-cell responses, preventing bacterial clearance [76, 77]. Additionally, people 
with chronic disease produce greater amounts of prostaglandin E2 and high 
levels of tumor necrosis factor, which cause immunosuppression in the host [76, 
78, 79]. Chronic Q fever patients also have increased IL-10 secretion, which is 
believed to control the inflammatory response and limit the pathogenic effects 
induced by C. burnetii allowing for prolonged infection [75]. Dysregulation of 
immune components clearly modulates the severity of Q fever disease; however, 
the role of host immune function in controlling bacterial infection requires further 
exploration and research.    
 The antimicrobial therapies prescribed to treat Q fever are based on the 
disease state. Standard treatment for acute disease is 100 milligrams per 
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kilogram (mg/kg) of doxycycline for 14 days. The primary alternative to 
doxycycline is fluoroquinolone therapy [46]. Suggested treatment for acutely 
infected pregnant women is cotrimoxazole 800 mg/kg until delivery [80]. Obstetric 
complications were observed in 81% of women who did not receive 
cotrimoxazole therapy during pregnancy [81]. Treatment of chronic disease is 
complicated and is often dependent on the observed disease manifestation. 
Synergistic therapy with hydroxychloroquine is often used to prevent resistance. 
The current recommendation is 200 mg doxycycline along with 600 mg of 
hydroxychloroquine daily for a minimum of 18 months [25, 81]. 
 Development of a human vaccine against C. burnetii has been 
investigated since the discovery of the bacterium. A live-attenuated vaccine 
produced and tested in Russia in the 1960’s [82, 83] was later abandoned over 
concerns of long-term persistence and potential development of endocarditis in 
vaccinated individuals [84]. A chloroform-methanol residue extracted vaccine 
was developed in the U.S. in the 1990s but was very reactogenic in animals and 
was never tested in humans [85]. A whole-cell formalin-inactivated Q fever 
vaccine (Q-vax) was developed and licensed for use in Australia and is currently 
given to high-risk individuals. This vaccine was prepared from the phase I 
Henzerling strain [13] and has been shown to be 100% effective in 
slaughterhouse workers years after vaccination [86, 87]. There are still concerns 
over the side effects of this vaccine in that it can cause severe reactions at the 
inoculation site [13, 88, 89]. It has also been associated with complications in 
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sero-positive patients, such that a pre-vaccination skin test is required for all 
vaccine recipients.   
Animal Disease 
  
Coxiella burnetii is able to infect a wide variety of both domestic and wild 
animal species. However, little is known about bacterial infection and 
pathogenesis in animals. The primary modes of transmission in animals are 
thought to be inhalation of infectious organisms and ingestion of contaminated 
feed and bedding [90]. Infection typically occurs during lambing and calving 
season, as contaminated aerosols are produced [54, 57, 91]. Additionally, C. 
burnetii-infected ticks are thought to be important in bacterial transmission 
among animals [90, 92]. C. burnetii infections in animals are generally 
asymptomatic but can cause reproductive complications, specifically stillbirths 
and abortions. Bacterial infection may also result in the birth of weak lambs, kids, 
or calves [93]. In most cases, abortion occurs at the end of gestation, with no 
previous clinical signs [53]. Aborted fetuses appear normal; however, the infected 
placenta typically has intercotyledonary thickening and discoloration [53].  Post-
parturient mammals can shed bacteria into the environment for long periods of 
time, while infected, non-pregnant animals do not regularly shed bacteria into the 
environment [52, 91]. C. burnetii is shed from the vaginal mucus, feces, and milk 
of infected goats, ewes, and cattle [58]. Shedding rates differ between species 
and route. C. burnetii has been detected in the vaginal mucus of infected ewes 
up to 71 days after parturition and cattle have been reported to shed 
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bacteria into milk up to 13 months after parturition [94, 95]. Additionally, cattle 
can shed the organism in their birth secretions for successive years and sheep 
have been documented shedding the bacterium in successive pregnancies  [94, 
96]. Infection appears to be persistent in pregnant animals and 
immunosuppression caused by pregnancy has been known to enhance 
multiplication of the organism [97]. Overall, C. burnetii infection can induce 
abortion in pregnant animals and cause prolonged shedding rates. In previously 
infected animals, the bacterium becomes dormant until pregnancy, at which time, 
a recrudescence of bacterial infection is observed. Information about bacterial 
infection in the reservoir host is necessary for the prevention of zoonotic disease.  
Diagnostics 
  
Diagnosing C. burnetii infection in cattle, sheep, and goats is essential in 
controlling the spread of infection to other animals and humans. As with other 
diseases, diagnosis of C. burnetii infection relies both on detecting the agent and 
host immune responses to the agent. Bacterial cultures are important diagnostic 
methods in determining presence of bacteria from environmental and host 
samples, but historically, C. burnetii has been impossible to culture in vitro due to 
the strict metabolic requirements and intracellular nature of the bacterium [1]. 
Recently, Omsland et al. developed a cell-free laboratory medium that meets the 
strict growth requirements necessary for C. burnetii growth [98]. Although this 
method is novel and interesting, it has not yet been adapted for real world 
diagnostic settings.  
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Infected animals are generally asymptomatic, but the presence of 
abortions may indicate C. burnetii infection within a flock or herd. Placental 
tissues from aborted animals can be stained for bacterial detection using the 
Gimenez or Machiavello staining methods [25, 53, 99]. Recent PCR and qPCR 
assays have been developed to determine the presence of bacteria in excreta, 
milk, and tissues. These assays amplify repetitive gene sequences found in the 
C. burnetii genome such as the IS1111 insertion gene [59, 100]. PCR assays 
have higher sensitivity and specificity to bacterial detection in animal samples 
(excluding serum) than other diagnostic methods, and may be the reason for the 
increase in the number of identified cases since the last decade [53]. Limitations 
of these PCR assays include their cost and inability to process at site of 
collection. However, it is essential to detect bacterial infection in herds early to 
prevent further spread and environmental contamination leading to future 
problems. In conclusion, diagnosing infections in animals is difficult due to the 
lack of specific clinical signs and the high frequency of subclinical infections. 
Therefore, a combination of serological testing and PCR assays are necessary to 
determine animal infection.   
Serological assays are the primary diagnostics used for detecting bacterial 
infection in humans. The OIE reference assay for detecting infection in animals is 
the complement fixation (CF) test. However, the CF test has low sensitivity and 
the antigen used often gives false-negative results [25, 53]. An alternative 
reference test used widely for serodiagnosis of Q fever is indirect 
immunofluorescence (IFA) [53, 72]. The IFA assay allows for the distinction 
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between acute and chronic disease by evaluating binding of patient antibodies to 
both C. burnetii phase I and II [101]. Cases in which the phase II antibody titer is 
higher than phase I are considered acutely infected, whereas high antibody titers 
to the phase I antigen signifies chronic disease [53]. Additional serodiagnostics 
include microagglutination, radioimmunoassay, and ELISA [47, 90, 101]. One 
constraint of all serodiagnostic assays is they cannot detect bacterial infection 
until seroconversion has occurred [53]. There is a considerable lag time where 
the host is infected but has not seroconverted, and serodiagnostic testing within 
that time will result in a false-negative diagnosis [53]. PCR assays are able to 
detect bacterial infection much earlier than serodiagnostic assays. However, 
serum cannot be used as a sample because it contains too few intracellular 
organisms [101]. Concurrent use of serodiagnostics, IFA and PCR, is necessary 
to determine infection in humans to ensure that bacteria can be detected at any 
stage of the infection. 
Treatment and Control 
 
Q fever is primarily spread to humans and animals by inhalation of 
infectious organisms. Therefore, specific measures must be taken to protect 
humans in contact with reservoir hosts, cattle, sheep, and goats. Suspect 
infected herds should be monitored with serodiagnostics and a variety of control 
measures have been advocated to minimize risk of infection. To prevent bacteria 
from contaminating the environment, contaminated birth products should ideally 
be incinerated [25]. Manure should not be spread during windy periods to prevent 
widespread contamination, and suspect infected manure should be treated with 
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lime or a 4% calcium cyanide solution [25, 53]. Tetracycline’s are often used to 
reduce the amount of bacterial shedding during parturition [53, 102]. Routine 
monitoring after infection is important in evaluating the progression of infection in 
the herd. However, negative results do not correlate with complete clearance of 
the bacterium as it is known to survive and remain infectious in the environment 
for long periods of time. Therefore, the only way to completely ensure prevention 
is through herd vaccination. 
Implementing herd vaccination protocols dramatically reduces 
environmental contamination and the incidence of human disease [25, 53]. The 
most effective vaccines for animals are made from inactivated phase I form of the 
bacterium [53, 103]. Souriau et al. evaluated the efficacy of vaccinating pregnant 
goats with phase I and II vaccines and challenging them with C. burnetii. In this 
study it was found that phase II vaccine was not protective against abortions and 
could not prevent bacterial shedding in the milk, feces, or vaginal secretions 
whereas the phase I vaccine reduced bacterial shedding from the placental 
tissue and excreted milk, but could not prevent shedding in the milk [104]. The 
authors determined that phase I vaccines were only protective for uninfected 
animals and failed to prevent shedding from previously infected animals [53, 
104]. Another downfall of the phase I vaccine is that vaccinated animals are 
indistinguishable from infected animals, which makes it difficult to determine 
which animals to vaccinate [53]. In conclusion, prevention of environmental 
contamination is essential for decreasing infection rates of humans and animals. 
Since the bacterium can survive in the environment for long periods of time, 
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infection cycles within herds will not be eradicated with antibiotic treatment alone. 
Herd vaccination programs are effective in decreasing bacterial shedding from 
animals and environmental contamination.      
Animal Models 
 
 The need for animal models for C. burnetii is two-fold; to elucidate 
bacterial pathogenesis in human and animal hosts, and to develop vaccines and 
drug therapies. Few studies have explored developing an animal model for 
animal disease. Experimental infection studies have been performed in cattle, 
sheep, and goats [32, 56, 58, 104-106]. These studies were essential in 
uncovering bacterial shedding rates and routes from post-parturient animals. 
Such studies also demonstrated the low incidence of bacterial shedding from 
non-pregnant animals. Infected, non-pregnant animals do not display clinical 
symptoms, but typically develop antibody titers after infection [32]. Additionally, 
histopathologic disease is minor to non-existent. Information about potential 
bacterial recrudescence in infected non-pregnant animals reveals that 
immunosuppression, as seen in pregnancy, can often lead to development of 
clinical disease [58, 103, 104]. These findings have also been shown in guinea 
pig and mouse experimental infections, where animals were immunosuppressed 
after inoculation, inducing bacterial infection [107]. Experimental infection studies 
in pregnant goats revealed bacterial shedding after multiple pregnancies, with 
bacterial latency occurring between pregnancies [58]. Similar findings have also 
been shown in experimental mouse infection studies where mice shed bacteria 
after successive pregnancies [108]. Bacteria appear to become latent in the 
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animal host, becoming reactivated during pregnancy-associated 
immunosuppression. The duration of this latency period has not been elucidated 
in the reservoir host. However, it is essential in understanding bacterial 
pathogenesis in small ruminants. Further experimental studies need to be 
conducted in pregnant and non-pregnant animal models to determine if bacterial 
latency occurs and where bacteria lay dormant until activation leading to clinical 
disease. Developing an animal model for animal disease is essential in 
understanding bacterial life cycle in the animal host in order to control infection 
and prevent transmission to other animals and humans. Additionally, animal 
models are necessary for developing vaccine and drug therapies that could be 
used to treat and prevent this latency period as well as shedding associated with 
immunosuppression. 
 Several rodent models have been developed for human Q fever; guinea 
pigs and mice are the most common models [73, 109-111]. Many rodent models 
mimic clinical and histopathologic disease associated with human acute Q fever 
when infected with the phase I form of C. burnetii; common symptoms include, 
fever, splenomegaly, and interstitial pneumonia [112]. Establishing rodent models 
for human chronic disease proves to be challenging. The primary hallmark of 
human disease is endocarditis, which is rarely observed in experimental 
infections in rodents, but has been observed in mice infected with large doses of 
phase I C. burnetii [111]. Recently, a mouse model that mimics human chronic Q 
fever was developed in transgenic-mice constitutively expressing IL-10 in 
macrophages [113]. Infection of these mice led to a persistent bacterial infection 
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in which macrophages were unable to kill C. burnetii, which is believed to be the 
situation in cases of chronic Q fever [113]. Development of this model was 
important in understanding bacterial persistence in the host. However, chronic 
histopathology (endocarditis) observed in human infection was not seen in 
infected transgenic mice. While no animal model truly mimics human acute and 
chronic disease, development of a mouse model for chronic disease revealed 
important information about bacterial persistence in the mouse host, which can 
be translated to human disease. In conclusion, continual efforts to develop an 
animal model for human infection are essential in understanding bacterial 
pathogenesis and developing effective vaccines for public health benefit.  
Future Directions for Coxiella Research 
 
 Forgoing review of C. burnetii shines on two areas of research that are in 
desperate need of resolution, vaccine development and diagnostics. Uncovering 
information about bacterial pathogenesis and development of chronic infections 
in reservoir hosts is essential in vaccine developmental research. Developing 
animal models for C. burnetii infections provides insight about the elusive nature 
of this bacterium filling the missing gaps in current knowledge
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CHAPTER 2: EFFECT OF INOCULATION ROUTE ON BACTERIAL  
INFECTION OF TISSUES AND DEVELOPMENT OF HISTOPATHOL OGIC 
LESIONS IN MICE INFECTED WITH COXIELLA BURNETII  
Introduction 
Coxiella burnetii is a gram-negative, intracellular bacterium that is 
commonly found in the environment and causes a disease termed Q fever in 
humans and coxiellosis in animals. Approximately 60% of human cases are 
asymptomatic, but Q fever pneumonia and hepatitis are common pathologies 
observed in symptomatic cases [64, 114]. Infection can occur in several ways 
with inhalation being the most common, followed by ingestion, and the bite of 
infected vectors, primarily ticks [115]. 
Regardless of the many routes of natural exposure, the majority of 
experimental mouse infection studies have used an intraperitoneal (IP) route of 
infection. The IP inoculation route is able to reproduce lesions commonly induced 
by the bacterium (pneumonia and hepatitis) but is not a natural route of infection 
and has questionable significance in the study of disease. Aerosol exposure 
would best model natural exposure; however, this method increases biohazard 
risks due to the production of infectious fine particle aerosols.
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Previous studies have evaluated C. burnetii infection in naturally 
susceptible as well as immunodeficient mouse strains including; A/J, SCID, and 
BALB/c strains. A study conducted in 1986 by George Scott et al., found that the 
A/J inbred mouse strain was most susceptible to C. burnetii infection, followed by 
the BALB/C strain; the most resistant mouse strain was C57BL/6 [112]. Infection, 
morbidity, and mortality rates in the susceptible mouse strains was much higher 
than the rates observed in the C57BL/6 mice [112].  
This project was initiated in order to establish a mouse model of 
coxiellosis that could be used in subsequent vaccine and pathogenesis trials.  
The specific objectives of this study were to determine if C57BL/6 mice develop 
similar infection and pathological lesions observed in infected humans and to 
compare two routes of inoculation, intraperitoneal (IP) and intranasal (IN), to 
observe differences in the pathogenesis and pathology of infected mice. This 
information will be used to develop an easy and efficient inoculation route in mice 
that replicates the common pathological lesions observed in natural infections.  
Two experiments were performed to assess disease and course of 
infection induced by C. burnetii in C57CL/6 mice. In Experiment 1, we evaluated 
route of inoculation, comparing intranasal versus intraperitoneal exposures, with 
the mindset that intranasal was a more natural route of exposure.  For 
experiment 2, we infected a larger group of mice by the intranasal route and 
maintained them for two months in order to evaluate long-term effects of 
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infection; these mice were also used as controls for the studies described in 
Chapters 3 and 4.  
Materials and Methods 
Animals  
 
Ten A/J (5 week-old female) and 50 C57BL/6 mice (30 five week-old 
females and 20 eight week-old females) were purchased from Charles River 
Laboratories (Wilmington, MA, USA). Mice were housed at the Colorado State 
University Infectious Disease Research Center in ventilated cages under HEPA-
filtered barrier conditions. Water and food were provided ad libitum. Animal care 
and use procedures were carried out in accordance with university policies [116]. 
Microorganism 
 
The Nine Mile Phase I strain (RSA493) of Coxiella burnetii, was obtained 
from the American Type Culture Collection (Manassas VA, USA). To prepare a 
working stock of the organism, 10 A/J mice were infected by IP inoculation (50 
uL) of the organism [2, 117]. Five mice were euthanized at seven days post 
inoculation (DPI) and five mice were euthanized at 11 DPI. Necropsies were 
performed, spleens were collected and pooled by mouse euthanasia date (7 or 
11 DPI) and stored at -80 degrees Celsius (°C). Spleens from five mice 
euthanized 7 DPI were thawed and homogenized with a Ten Broeck grinder, 
diluted to a final volume of 40 ml in phosphate buffered saline (PBS) without 
additives, and was stored in 1 ml aliquots at -80°C.  
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Mouse Infection Experiments   
Mice were infected with 3000 C57BL/6 infectious dose 50% (ID50) splenic 
stock homogenate. Briefly, C57BL/6 mice were intranasally inoculated with serial 
tenfold dilutions of splenic stock homogenate 10E0 to 10E-6, five mice in each 
dilution group. Seven days after infection, mice were euthanized and splenic 
tissue was collected for conventional PCR analysis. The number of PCR positive 
splenic samples in each dilution group determined subsequent ID50.  
Thirty C57BL/6 mice were randomly allocated into two inoculation route 
groups (15 per group). Mice inoculated IN were anesthetized prior to challenge 
with an IP inoculation of ketamine and xylazine (100 and 10 mg/kg respectively). 
Three mice from each inoculation group were euthanized and characterized on 
days 7, 14, 21, 28, and 35 post-inoculation. In a second trial, 20 C57BL/6 mice 
received the same inoculation dose and route as listed above. Five mice were 
euthanized at 14 and 28 DPI; the remaining 10 mice were euthanized at 59 DPI. 
All mice were checked daily for mortality and morbidity. 
Necropsies were performed at each time point and sections of the spleen, 
liver, lungs, heart, and kidney were collected in 10% neutral-buffered formalin. 
The size of the spleen was reviewed and recorded on a graded scale of 1 to 4, 
with 1 indicating a normal sized spleen and 4 being grossly enlarged 
(approximately ≥ four times the size of normal). Tissues were embedded in 
paraffin, and 5-micrometer sections were stained with hematoxylin and eosin for 
microscopic review, Dr. Colleen Duncan conducted all histopathologic 
evaluations. One half of the spleen from each mouse was aseptically collected 
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and stored at -80°C for DNA extraction. Bone marrow samples were collected for 
the 20 intranasally inoculated mice in Experiment 2, by flushing the femoral 
cavity with 0.5 ml of PBS and storing those samples at -80°C for quantitative 
PCR analysis.  
Infection was characterized by conventional and quantitative polymerase 
chain reaction (PCR) and indirect immunofluorescence assays (IFA). Details of 
PCR assays are listed in Table 2. For quantitative PCR, a threshold cycle (Ct) 
less than 38 indicated bacterial DNA presence in the spleen.  
Microbiological Assays  
Immunofluorescence detection of bacteria. Approximately 10 mg of spleen 
was squashed between two microscope slides and fixed in 70% acetone for at 
least 12 hours. These splenic squash mounts were stained with a rabbit 
antiserum against the C. burnetii Nine Mile Phase I antigen (Critical Reagents 
Program, Frederick, MD, USA). This primary antibody was prepared as a dilution 
of 1:2500 with 1% equine serum. Slides were placed in a 37°C humidity chamber 
for 30 minutes (min) washed in PBS for 10 min, and rinsed in distilled water 
(dH20) for 30 seconds (sec). Slides were air dried and then stained with DyLight 
488-labeled goat anti-rabbit secondary antibody (Jackson ImmunoResearch 
Laboratories, West Grove, PA, USA) diluted 1:800 with PBS. Slides were again 
placed in the humidity chamber for 30 min, followed by washing as stated above. 
The slides were air-dried and mounted with Dako mounting media (Carpinteria, 
CA, USA). Slides were randomly labeled, and reviewed in a blinded manner 
under a total magnification of 400X (Olympus FSX-100, Center Valley, PA, USA). 
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The strength of the fluorescence signal was subjectively graded on a scale from 
0-3, with 0 designated as negative fluorescence and 3 as a strong signal of 
fluorescence examples of graded images are shown in Figure 1.  
 
  
Figure 1. Examples of the IFA Grading Scheme.  
A score of 3 indicates a strongly positive fluorescent signal 2, a moderate 
positive fluorescent signal, and 1 a very mild signal. Negative samples were 
given a score of zero. 
3 2 
1 0 
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PCR assays.  Bacterial DNA extraction was performed on mouse splenic 
samples using a QIAGEN QIAamp DNA mini kit (Valencia, CA, USA). Ten 
milligrams of splenic tissue from each mouse was weighed and used in the 
extraction protocol according to manufacturer’s instructions. Extracted DNA was 
precipitated in ethanol (EtOH). The precipitate was centrifuged at 14,000 x g for 
15 min the pellet was washed in 1 ml of 70% EtOH then allowed to air dry.  The 
DNA pellet was resuspended in 50 uL of TE (10 mM Tris, 1 mM EDTA, pH 8.0) 
and DNA concentration analyzed using a Thermo Scientific NanoDrop 1000 
spectrophotometer (Rockford, IL, USA); OD 260/280 were evaluated to assess 
purity. All samples were diluted to a final concentration of 100 ng in 5 uL with TE.   
Primers were designed using the primer-basic local alignment search tool 
(Primer-BLAST) software (National Center for Biotechnology Information, 
Bethesda, MD, USA) to amplify an 861 base-pair fragment of the insertion 
sequence gene IS1111 found in approximately 20 copies in the Nine Mile phase I 
genome [11]. Conventional PCR was performed on the splenic DNA samples. 
Primer sequences and cycling conditions are listed in Table 1. 
The PCR amplicon was separated by electrophoresis on a 1% agarose 
gel prepared with ethidium bromide, and was purified using a QIAquick PCR 
purification kit for band extraction and analysis (QIAGEN Inc., Valencia, CA, 
USA). The extracted amplicon was sent to the University of California Davis 
proteomics laboratory for nucleotide sequencing. 
Quantitative PCR (qPCR) assays were conducted using primers and 
probe based on previously published assays to amplify the Nine Mile IS1111 
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sequence [51, 118]. Primers, fluorescent probes, and cycling conditions, are 
listed in Table 1. Serial ten-fold dilutions of the amplicon obtained by 
conventional PCR were prepared with TE and used as a standard curve for each 
qPCR assay. In order to compare variability between assays, the threshold for 
each run was set at 1000. 
Table 1.  
PCR Primers and Amplification Conditions. 
Primer Name  
Sequence of 
 Primer or Probe (5’- 3’) 
Concentration 
nM 
Cycling 
Conditions 
Amplicon 
Size 
(bp) 
Standard PCR   95°C (20 sec), 
60°C (60 sec), 
72°C 
(2 min) x  
40 cycles 
 
IS1111F3 
GCGAGCGAAGCGGTGGGATT 
500   861 
IS1111R22 
AGCCCGTATGCAGCGAAGCG 
500    
Quantitative PCR   95°C (10 min) x 
1 cycle 
95°C (15 sec), 
60°C (60 sec) x 
40 cycles 
 
IS1111F 
CCGATCATTTGGGCGCT 
1600   63 
IS1111R 
CGGCGGTGTTTAGGC 
800    
IS1111P* 
TTAACACGCCAAGAAACGTATC
-GCTGTG 
200    
*Fluorescent oligonucleotide probe labeled with 5’ FAM and 3’ fluorescence 
quencher (BHQ). 
BP: base pair length of amplicon.
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Statistical Analyses 
 
Mean splenic genome equivalent (GE) values for IP and IN inoculation 
routes and euthanasia groups “early” and “late” were compared using analysis of 
variance (ANOVA) test. For the IN control inoculated mice in experiment 2, mean 
splenic and bone marrow GE values were compared between mice euthanized 
“early” days 14 and 28 post inoculation and “late” mice euthanized 59 DPI using 
ANOVA.  A GE value less than 5 was converted to a value of 1 for statistical 
analysis. Categorical variables including IFA score, DPI, and inoculation route for 
IP and IN inoculation groups were compared using the Pearson’s Chi-square test 
and odds ratios (where applicable). The Fischer’s exact test (FET) was used to 
evaluate groups with categorical frequencies less than five. IFA scores were 
dichotomously grouped; negative to weakly positive spleen samples (IFA scores 
0 and 1) were considered negative, while mild to moderately positive samples 
(IFA scores 2 and 3) were considered positive. Mice in the inoculation route 
study were dichotomously grouped by their euthanasia date; “early,” days seven, 
14, and 21 after infection, and “late,” days 28 and 35 post inoculation. The 
frequency of splenomegaly, histopathologic lesions, and IFA scores were 
evaluated between “early” and “late” mouse groups. Infected control mice were 
also dichotomously grouped by their euthanasia dates. Infected control mice in 
the “early” group were euthanized on days 14 and 28 post inoculation; while mice 
in the “late” group were euthanized 59 DPI. Statistics were performed using 
SPSS software (IBM, version 19, Somers, NY), p-values ≤0.05 were considered 
significant for all tests.   
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Results 
Experiment 1: Evaluation of IP versus IN Inoculatio n Route 
 
There were no observable clinical signs of disease or mortality in any 
mouse throughout the 35-day time course of infection. Splenic enlargement 
evident at necropsy was observed in 3 of 15 IN and 6 of 15 IP inoculated mice 
(pooled across euthanasia time points), a difference that was not statistically 
significant (p=0.4, FET). Splenomegaly was observed in 6 of 18 mice euthanized 
7, 14, and 21 DPI and 3 of 12 mice euthanized 28 and 35 DPI this was not a 
statistically significant difference (p=0.5, FET). 
Hepatitis was characterized by aggregates of lymphocytes and histiocytic 
cells randomly distributed throughout the parenchyma (Figure 2A). Larger foci 
were associated with hepatocyte degeneration and loss. Hepatitis was observed 
in 10 of 15 IP and 8 of 15 IN inoculated mice, which was not a statistically 
significant difference (OR: 1.8, 95% CI: 0.4-7.7). Hepatitis was observed in 5 of 9 
mice euthanized at both the “early” (7, 14, and 21 DPI) and “late” (28, 35 DPI) 
time points, and was not a statistically significant difference (p=0.7 FET).  
Bronchopneumonia characterized by a focus of suppurative inflammation 
centered around large airways (Figure 2B) was observed in 4 of 9 IN inoculated 
mice at days 7 and 14 post infection, but was not observed in IP inoculated mice 
at any time point, this difference was not statistically significant  (p=0.1, FET). 
Mild interstitial pneumonia, characterized as a patchy expansion of interlobular 
septae by lymphocytes and plasma cells (Figure 2C) was observed in 9 of 15 IP 
and 10 of 15 IN inoculated mice, and was not a statistical difference between 
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inoculation routes (OR: 0.8, 95% CI: 0.17-3.3). Ten mice were from the “early” 
group (euthanized 7, 14, and 21 DPI), and 9 mice were from the “late” group 
(euthanized 28, 35 DPI). There was no statistically significant difference in the 
frequency of interstitial pneumonia observed between these mouse groups 
(p=1.0, FET).  
Histologic lesions were also observed in the heart and kidney of infected 
mice. Myocarditis, characterized as small aggregates of lymphocytes and plasma 
cells distributed throughout the myocardium (Figure 2D), was observed in 10 of 
30 mice, five from each inoculation group, a difference that was not statistically 
different between inoculation routes (OR: 1, 95% CI: 0.22-4.6). There was no 
difference in the frequency of myocarditis between “early” and “late” mouse 
groups (p=1.0, FET). Rare mononuclear interstitial nephritis was observed in 4 of 
15 IP and 2 of 15 IN inoculated mice. There was no difference in the frequency of 
nephritis between inoculation routes or between “early” and “late” mouse groups 
(p=0.7, FET). Splenic lymphoid hyperplasia was observed in 1 IN inoculated 
mouse euthanized at 14 DPI, but was not seen in any other mouse throughout 
the infection time course.  
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Figure 2. A-D)  Histopathologic lesions associated with C. burnetii infection. 
 A) Hepatitis, B) bronchopneumonia, C) interstitial pneumonia, D) myocarditis. 
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Table 2.  
Comparison of C. burnetii Infection in Mice Inoculated by the Intraperitoneal and 
Intranasal Routes. 
Inoculation 
Route 
DPI of 
Necropsy 
Number of 
Mice 
Splenic PCR  
GE* value (mean +  SD) 
IP 7 3 79.8 + 136.5 
IN 7 3 8.5+ 7.5 
IP 14 3 82.2 + 19.4 
IN 14 3 113.7 + 132.7 
IP 21 3 3.5 + 4.4 
IN 21 3 7.7 + 6.8 
IP 28 3 3.4 + 4.0 
IN 28 3 1.0 + 0.0 
IP 35 3 3.4 + 4.2 
IN 35 3 11.9  + 18.9 
IP All 15 34.5 + 65.4 
IN All 15 28.6 + 65.3 
*GE: genome equivalent, values <5 were converted to a value of 1 for statistical 
analysis.  
IP: intraperitoneal inoculation 
IN: intranasal inoculation 
DPI: days post inoculation. 
SD: standard deviation. 
IFA: indirect immunofluorescence assay. 
 
The mean GE values for mouse splenic tissue, inoculation route, and 
euthanasia DPI are listed in Table 2. Comparison of mean GE values revealed 
no significant difference in the amount of bacteria in the spleen between IP and 
IN infected mice or between mice in “early” and “late” groups (F: 1.2, DF: 3, 
p=0.3). The IFA scores assigned to splenic squash mounts ranged from negative 
to moderately positive. There was no statistically significant difference in the 
frequency of positive IFA scores between inoculation routes (OR: 1, 95% CI: 
0.22-4.6).   
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Experiment 2: Long-term Infection Following Intrana sal Inoculation of C.  
burnetii. 
 
There were no observable clinical signs in any of the 20 IN inoculated 
control mice throughout the 59-day infection time course. One mouse did not 
recover from anesthesia after the inoculation, blood was collected and a 
necropsy was performed. Splenomegaly was observed in 15 mice from 
experiment 2; 5 from the “early” group (mice euthanized 14 and 28 DPI) and 10 
from the “late” group (mice euthanized 42 and 59 DPI). Mice in the “late” group 
were two times more likely to have splenomegaly than mice in the “early” group 
(95% CI; 0.27-0.93).  
The same histopathologic lesions described for inoculated mice in 
Experiment 1 were also observed in the mice in this experiment. Hepatitis was 
observed in 9 of 10 mice from the “early” group and 8 of 10 mice from the “late” 
group, and was not statistically significant between mouse groups (p=0.5, FET). 
Interstitial pneumonia was observed in 8 of 10 mice from the “early” group and 1 
of 10 mice from the “late” group, and was a statistically significant difference 
between mouse groups (p=0.001, FET). Mild myocarditis was observed in 4 of 10 
mice from the “early” group and 1 of 10 from the “late” group, a difference that 
was not statistically significantly (p=0.3, FET). Interstitial nephritis was observed 
in 3 of 10 mice from the “early” mouse group, and 0 of 10 mice from the “late” 
group; the difference between mouse groups was not statistically significant 
(p=0.9, FET). Mild splenic lymphoid hyperplasia was observed in 8 of 10 from the 
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“early” and 10 of 10 from the “late” group; the difference between mouse groups 
was not statistically significant (p=0.5, FET).   
 Mean GE values, including standard deviations, for splenic and bone 
marrow samples are listed in Table 3. There was no statistically significant 
difference in the amount of bacterial DNA detected in the splenic tissue of mice 
from “early” and “late” groups (F: 1.4, DF: 1, p=0.3), or in the amount of bacterial 
DNA detected in the bone marrow (F: 3.3, DF: 1, p=0.1). IFA results were 
significantly different between “early” and “late” mouse groups; 4 of 9 “early” mice 
had IFA positive samples compared to 0 of 10 samples from the “late” group 
(p=0.02).  
Table 3.   
Comparison of the Amount of Bacterial DNA Detected in C. burnetii Infected  
Tissues and the Duration of Infection. 
Mouse 
Group 
Necropsy 
DPI 
Number 
of Mice 
Splenic  
qPCR GE* 
(Mean ± SD) 
Bone Marrow 
qPCR GE*  
(Mean ± SD) 
“Early” 14, 28 4,5 13.5 ± 4.5 10.4 ± 6.0 
“Late” 59 10 0.2 ± 0.1 1.0  ± 0.0 
Total 14, 28, 59 19 8.3 ± 12.3 2.6 ± 5.4 
*GE: genome equivalent, values <5 were converted to 1 for statistical analysis.  
DPI: days post inoculation.  
SD: standard deviation. 
Discussion 
 
This study demonstrated that the C57BL/6 mouse strain is readily infected 
with the Nine Mile phase I strain of Coxiella burnetii and failed to develop clinical 
disease, but did manifest a number of the lesions associated with coxiellosis in 
humans and other animals. Hepatitis was the most common pathology, seen in 
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84% of all infected mice. Hepatic lesions were not observed in any IN inoculated 
mice until 14 days after infection, but were observed in all IP inoculated mice 
throughout the infection time course. These results suggested that the IP 
inoculation route may have induced a faster systemic immune response and 
hepatitis was seen in IP mice earlier than IN inoculated mice, or that the IP route 
provided a more direct access for the bacteria to infect mouse liver tissue. The 
similar frequency of hepatic lesions observed between IP and IN inoculated mice 
at later time points suggested that the inoculation route was a factor at early time 
points but is not a confounding factor at later time points.  
Slight variations in pulmonary lesions were evident between inoculation 
routes. Four IN infected mice developed bronchopneumonia after inoculation, 
which was not observed in any IP infected mice. Bronchopneumonia, 
inflammation of the lung originating from the major airways and is most 
commonly caused by inhalation of an airborne pathogen or foreign material.  As 
such, the pattern of inflammation in the lung of the IN inoculated mice euthanized 
at early infection time points was interpreted as secondary to the inoculation 
procedure and not necessarily the agent. Further, the lesion was not seen in 
mice after 14 days post inoculation suggesting that bronchopneumonia resolved 
over time. Mild interstitial inflammation was seen with equal frequency in both 
inoculation groups and is consistent with hematogenous dissemination, which 
has been previously described [119]. In the IN inoculated control mice, interstitial 
pneumonia was seen at a higher frequency in mice euthanized at the early 
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infection time points than mice euthanized at 59 DPI; suggested resolution of 
bacterial infection from the lung tissues over time.   
Myocarditis is a severe manifestation associated with C. burnetii infection. 
This lesion developed independent of inoculation route and was observed in the 
same frequency in both IN and IP infected mice. In the IN inoculated control 
mice, myocarditis was observed in only one mouse 59 DPI, indicating bacterial 
resolution over time. Myocarditis has not been previously described in any inbred 
mouse strain following intranasal inoculation with the Nine Mile Phase I strain of 
C. burnetii. However, previous studies have observed myocarditis in mice and 
guinea pigs infected with C. burnetii by the intraperitoneal and aerosol routes [73, 
93].  
Lymphoid hyperplasia, described as a non-specific inflammatory lesion 
associated with the spleen was observed in the majority of infected mice. 
Development of this lesion was most likely induced by up-regulation of the 
immune system in relation to bacterial infection, and has been described in 
previous mouse infection studies [1, 2, 4]. A second non-specific inflammation 
was observed in the kidneys of infected mice. Rare interstitial nephritis was 
observed in mice from each inoculation group, but was not observed in any 
mouse 59 DPI. This lesion appeared to be inflammatory in nature, which 
suggested that the tissue was reacting to the bacterial infection by stimulating 
production of immune cells. Observations of histopathologic lesions induced by 
C. burnetii infection in the IN inoculated control mice revealed that lesions 
associated with the lungs, kidneys, and heart were less common approximately 
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two months after infection. However, lesions associated with the liver were still 
observed at high frequencies 59 days after infection. This information 
demonstrated that the bacterium might have induced a long-term infection in the 
liver tissue of infected mice. 
Bacterial infection of mouse tissues was similar between IP and IN 
infected mice, demonstrating that dissemination and infection are independent of 
inoculation route. In the IN inoculated control mice, a high frequency of bacterial 
DNA was detected in the splenic tissue of infected mice 28 days after infection, 
which decreased significantly at 59 DPI. In both studies, the highest frequency of 
IFA positive samples was observed between 14 and 21 DPI, and no positive 
samples were observed from the splenic tissue of mice euthanized at 59 DPI. 
Together, these results demonstrated that bacterial DNA detection in the spleen 
was highest early during the infection and declined approximately one month 
after infection. Conversely, bacterial DNA detection in the bone marrow of IN 
inoculated control mice euthanized at 59 DPI was higher than mice euthanized at 
14 and 28 DPI. Collectively, these data support the concept that persistence of 
C. burnetii varies among tissues, which may have important implications for 
chronic and recrudescent disease. An increase in bacteria in the bone marrow 
demonstrated a potential bacterial sequestering and possible development of 
chronic infection, as has been described in human cases of Q fever [120, 121].   
The most common pathology associated with human acute Q fever 
includes hepatitis and pneumonia [122]. In contrast, chronic disease in humans is 
typically seen as endocarditis, and less common, osteomyelitis [120]. In humans, 
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splenomegaly associated with non-culturable endocarditis, is clinically suggestive 
of Q fever [73, 74]. This study found that the most common lesions observed in 
infected mice were hepatitis and interstitial pneumonia, followed by, myocarditis, 
nephritis, and splenic lymphoid hyperplasia. Development of these lesions was 
independent of the route of infection. The lesions associated with the heart, lung, 
and kidneys observed in infected mice were less common two-months after 
infection. Pathologies related to the spleen and liver, were still observed 59 days 
after infection, which demonstrated that intranasal infection with C .burnetii 
induces pathologic lesions and bacterial infection in mouse tissues that remain 
two months after initial infection. Also, that the C57BL/6 inbred mouse strain 
develops similar pathology to humans when infected with C. burnetii, and the 
route of exposure did not confound this finding.  
 Given the frequency of inhalation as a means of exposure in naturally 
acquired Coxiella burnetii human infections [76], it is important to replicate this 
exposure route and pathology development in an animal model. By being able to 
study infection in an animal model, pathogenesis of the organism can be 
elucidated. The present study demonstrated that the IP and IN inoculation routes 
do not differ in their ability to infect or induce pathologic lesions in the mouse; 
however, there are subtle differences in the pathology present at early time 
points that researchers should be aware of. In this study, the C57BL/6 inbred 
mouse strain developed similar histopathology observed in naturally infected 
humans. The retention of pathologies of the liver two months after initial infection 
provides insight about long-term infection after natural exposure. These results 
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suggest that the intranasal route is an acceptable route of inoculation for future 
studies as it mimics natural pathogenesis of infection, results in similar 
quantitative microbiological findings as both IP and aerosol inoculation studies, 
and is a safer and more efficient than other inoculation methods.   
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CHAPTER 3: EFFECT OF AGE AND CHEMICALLY INDUCED 
IMMUNOSUPPRESSION IN MICE 
Introduction 
The intracellular bacterium Coxiella burnetii is the causative agent of the 
human disease Q fever. Based on serum antibody titers to C. burnetii phase I or 
II antigens and the development of histopathologic lesions, disease is classified 
as either acute or chronic.  Acute Q fever is generally asymptomatic but clinical 
signs may include flu-like symptoms, pneumonia, hepatitis, and 
menigoencephalitis [70]. Chronic Q fever occurs in approximately 1-2% of 
acutely infected cases [64]. Chronic disease commonly manifests as 
endocarditis, typically observed in patients with previous valvulopathies [70, 123], 
and less often as osteomyelitis and glomerulonephritis [70, 124].  
There are many theories regarding why certain disease manifestations 
develop in C. burnetii infections, and studies have shown trends in specific 
pathologies related to genotype and geography and the route of exposure. Cases 
of Q fever pneumonia are more common in Spain and Canada, while cases of 
hepatitis are more commonly observed in France and Australia [70]. Q fever 
pneumonia has been more frequently described in cases of inhalation, while 
hepatitis has been more frequently described in cases of infection by ingestion 
[70]. Additional factors that may determine severity of C. burnetii infection include
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inoculation dose, bacterial molecular characteristics (phase and strain), and the 
relationship between the bacterium and the host [32, 69, 125]. 
Host factors are also important in disease development and may 
determine the severity of pathological lesions associated with C. burnetii 
infection. Age appears to be an important host attribute, with the majority of Q 
fever cases observed in humans over the age of 15 years [71]. Q fever is often 
associated with occupation and most often infects people in close contact with 
reservoir hosts including, ranchers, abattoir workers, and veterinarians [126]. 
Immune status also appears to be an important factor during C. burnetii infection. 
Disease manifestations are typically seen in patients with immune disorders in 
which the cell mediated immune response is insufficient [32]. Chronic Q fever 
has been described in patients with acquired immunodeficiency syndrome, 
cancer, and leukemia [70], suggesting that host immune status may have an 
association in the severity of disease.  
The following experiments were designed to evaluate the effects of age 
and immunosuppression on the development of clinical and pathological disease 
in mice infected with C. burnetii. This information is important for the 
development of a mouse model that will mimic disease manifestations observed 
in humans for the future goal of drug and vaccine development.   
To evaluate the effect of age, two different age groups of mice were 
attained, 9 months and 9 weeks. In order to evaluate immunosuppression, mice 
were treated with either dexamethasone or cyclophosphamide with doses that 
have been previously described [127, 128]. Dexamethasone is a glucocorticoid 
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that suppresses the cell mediated immune response of the host by inhibiting 
genes that encode for production of cytokines, which reduces T cell proliferation 
essential in resolving C. burnetii infection [129]. Dexamethasone also affects the 
humoral immune response of the host by inducing B cells to produce smaller 
amounts of IL-2 receptors and cytokine important in the proliferation of B and T 
lymphocytes [130]. In addition to its effects on cell mediated and humoral 
immune responses of the host, dexamethasone down-regulates Fc receptors on 
macrophages which causes less efficient phagocytosis of opsonized cells [131]. 
Overall, this study is attempting to induce prolonged C. burnetii infection in mice 
with exacerbated pathologic disease observed in chronic Q fever cases by 
treating mice with dexamethasone.  
 Cyclophosphamide is a cytostatic alkylating agent that can induce 
immunosuppression when given at high doses [132]. The following study evaluated 
cyclophosphamide-induced immunosuppression in mice infected with C. burnetii. 
Cyclophosphamide suppresses proliferation of T lymphocytes via a nitric oxide (NO) 
pathway, which works by priming immunosuppressive myeloid progenitors for iNOS 
protein synthesis [133]. Additionally, cyclophosphamide reduces the number and the 
suppressive ability of regulatory T cells (TREGs), which are essential in regulating the 
host immune response [132]. Cyclophosphamide can induce immunosuppression by 
modulating and promoting changes in the host immune cells. This experimental 
mouse study will reveal if treatment with cyclophosphamide will exacerbate C. burnetii 
disease.  
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 Overall, the following mouse experimental infection studies will determine 
if mouse age or treatment with dexamethasone or cyclophosphamide results in 
prolonged coxiellosis and exacerbated clinical and histopathologic lesions 
associated with infection. The first study examines age and dexamethasone-
treatment while the second study determines if cyclophosphamide treatment 
before or after infection alters disease progression in mice.  
Materials and Methods  
 
Animals   
Ten A/J (5 week-old female), and 62 C57BL/6 (39 nine-week-old and 24 
nine-month-old female) mice were purchased from Charles River Laboratories 
(Wilmington, MA, USA). Mice were housed at the Colorado State University 
Infectious Disease Research Center in ventilated cages under HEPA-filtered 
barrier conditions. Water and food were provided ad libitum. Animal care and use 
procedures were carried out in accordance with university policies [116].    
Microorganism   
The Nine Mile Phase I strain (RSA493) of C. burnetii was obtained from 
the American Type Culture Collection (Manassas VA, USA). Stocks were 
prepared as homogenates of pooled spleens from A/J mice inoculated 
intraperitoneally 7 days previously (see Chapter 2) and stored in aliquots at 80oC 
[2, 117].  
Mouse experimental infections   
Sixty-two C57BL/6 mice were separated into groups (A-G) based on the 
planned euthanasia day and treatment received, as summarized in Table 1. All 
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mice were inoculated IN with 3000 C57BL/6 ID50 splenic stock homogenate 
diluted with phosphate buffered saline (PBS) described in Chapter 2. Mice were 
anesthetized prior to inoculation with a mixture of ketamine and xylazine (100 
and 10 mg/kg respectively) injected intraperitoneally.  
In addition to the two mouse ages examined, two immunosuppressive 
protocols were evaluated.  First, dexamethasone sodium phosphate (SP) 
(Bimeda-MTC Animal Health Inc., Ontario, Canada) was added to drinking water 
at a concentration of 8 ug/ml, a modified dose from a previous study [127]. The 
water was changed and fresh solution of drug was provided every other day for 
the duration of the study. Second, 15 mice were immunosuppressed by IP 
treatments with cyclophosphamide (Mead Johnson, Evansville, IN, USA) at a 
dose of 150 mg/kg, as previously described [128].  Cyclophosphamide treatment 
was initiated prior to infection for some mice and after infection for others. Mice in 
groups G and H were described in Experiment 2, Chapter 2. Four mice were 
euthanized 14 DPI and five mice were euthanized 28 DPI, from group G. All mice 
from group H were euthanized at 59 DPI.  
On the scheduled day of euthanasia, mice were anesthetized with 
ketamine-xylazine and a terminal blood sample was collected by cardiac 
puncture. The mice were then euthanized and samples of spleen, liver, lung, 
heart, and kidney were collected into 10% neutral-buffered formalin. Those tissue 
sections were paraffin embedded, cut in 5-micrometer sections, and stained with 
hematoxylin and eosin for microscopic review; Dr. Colleen Duncan conducted all 
histopathologic evaluations. Splenic enlargement was graded on a scale from 0-
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5; with 0 indicating a smaller than average spleen size, 1 an average sized 
spleen, and 5 a grossly enlarged spleen (approximately ≥ 5 times larger than 
average). Half of each spleen was stored at -80°C for D NA extraction. Bone 
marrow samples were collected by washing femur cavities with 0.5 ml of PBS 
and stored frozen at -80°C until assay.  
Table 1.  
Age and Immunosuppression Study Experimental Design. 
Group 
9 Week 
Mice (n) 
9 Month 
Mice (n) 
Immunosuppression 
Treatment 
Day of Euthanasia 
(DPI) 
A 7 8 None 14 
B 8 8 DEX, DPI 28 to 42 42 
C 8 8 None 42 
D 5 0 CY initiated on -3 
DPI 
14 
E 5 0 CY initiated on -3 
DPI 
28 
F 5 0 CY initiated on DPI 
28 
42 
G** 10 0 None 14, 28 
H** 10 0 None 59 
** Mice in groups G and H were part of the studies described in Chapter 2, 
Experiment 2. 
DEX: dexamethasone in drinking water. 
CY:  cyclophosphamide delivered by IP injection. 
Assays for Detection of C. burnetii 
 
Indirect Immunofluorescence Assay (IFA).  Approximately 10 milligrams of 
spleen were used to prepare splenic squash mounts.  Slides were fixed in 70% 
acetone for at least 12 hours, then immunostained and evaluated as described in 
Chapter 2.  Fluorescence signal was subjectively graded on a scale from 0-3, 
with 0 designated as negative fluorescence, and 3 designated as a strong signal 
of fluorescence.   
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Polymerase Chain Reaction (PCR).  Bacterial DNA extraction was performed 
on mouse splenic and bone marrow tissue samples and both conventional and 
quantitative PCR assays were conducted to detect the C. burnetii insertion 
sequence IS1111 gene as described in Chapter 2.   
Statistical Analyses 
 
Histopathology scores and tissue bacterial DNA infection (qPCR) results 
for group B (dexamethasone-treated) mice were compared to groups A and C 
(infected control mice). Histopathology and bacterial infection for groups D, E, 
and F (cyclophosphamide-treated) were compared to control mice in groups G 
and H (from previous experiment 2 in Chapter 2). Mean splenic and bone marrow 
bacterial genome equivalent (GE) values between mouse groups were compared 
using analysis of variance (ANOVA). GE values less than 5 were converted to a 
value of 1 for analysis. Mouse samples that fell below the detectable qPCR 
threshold value of 1000 were converted to missing values in SPSS to ensure 
accuracy when statistically evaluating quantitative data. The Pearson’s Chi-
square test and odds ratio (OR), when appropriate, were used to compare 
frequencies of categorical data. Fischer’s exact test (FET) was reported for 
categorical variables in which the frequency was less than five. The presence of 
splenomegaly and IFA scores were dichotomously categorized into positive and 
negative for analysis. Spleens graded 2-5, and IFA scores 2-3 were considered 
positive. When interaction between variables was identified, stratum specific 
measures of effect were reported. The Mantel-Haenszel test was used to assess 
confounding among categorical variables. A p-value ≤ 0.05 was considered 
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significant for all tests. All statistical analyses were performed using SPSS 
software (IBM, version 19, Somers, NY).  
Results 
Clinical Signs and Gross Pathology 
 
Morbidity was not observed in any mice throughout the 42-day time 
course of infection. One 9-week-old mouse from group A and one mouse from 
group G died following anesthesia and inoculation; necropsies were not 
performed. 
Splenomegaly was observed in 16 of 42 mice from groups A and C, but 
was not observed in any dexamethasone treated mouse from group B. This 
difference was statistically significant (p=0.02, FET). There was no difference in 
incidence of splenomegaly between mice euthanized at different time points; 
enlarged spleens were observed in 12 of 15 mice from group A, euthanized 14 
DPI, compared to 4 of 32 mice from groups B and C, euthanized 42 DPI (p=0.4, 
FET). Splenomegaly was seen in 15 of 20 mice from control mice in groups G 
and H, and 4 of 15 mice from cyclophosphamide-treated groups D, E, and F.  
Mice in groups G and H were 10.3 times more likely to have splenomegaly than 
cyclophosphamide mice in groups D, E, and F (95% CI: 2.2-47.3). Splenomegaly 
was seen in 3 mice from groups D, E, and G (euthanized 14 and 28 DPI) 
compared to 1 mouse from group F (euthanized 42 DPI) and was not a 
statistically significant difference (p=0.8, FET). However, duration of infection was 
a significant interaction term in the comparison of splenomegaly and 
cyclophosphamide treatment. There was no significant difference in 
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splenomegaly between groups D, E, and G, euthanized 14 and 28 DPI 
respectively, (p=0.4, FET), but there was a significant difference in incidence of 
splenomegaly between mouse groups F and H, euthanized 42 and 59 DPI 
(p=0.004, FET). Also, there was no statistically significant difference in 
splenomegaly between mice that began cyclophosphamide-treatment three days 
before infection (groups D and E) and mice that began cyclophosphamide 
treatment 28 DPI (group F; p=0.08, FET).  
Histopathology 
Hepatic lesions were seen in 47 of 62 infected mice and characterized as 
either inflammatory or degenerative. Inflammatory changes were 
lymphohistiocytic in nature with many small microgranulomas randomly 
distributed throughout the hepatic parenchyma (Figure 1A). In two mice, central 
coagulative necrosis with inflammatory foci and a rim of peripheral lymphocytes 
was observed. The second histologic pattern of liver disease was vacuolar 
degeneration of hepatocyte cytoplasm. This lesion was observed in all 16 
dexamethasone-treated mice from group B (Figure 1B) and was not seen in any 
mice from groups A and C, ascribing to the drug treatment rather than infection. 
Hepatic lesions were observed in 12 of 23 young and 21 of 24 aged mice from 
mouse groups A, B, and C. There was a significant difference in the incidence of 
hepatitis associated with mouse age; aged mice were 6.4 times more likely to 
develop hepatitis compared to young mice (95% CI: 1.6-25.8). Duration of 
infection (14 versus 42 DPI) was a significant interaction term when evaluating 
frequency of hepatic lesions between young and aged mice. Hepatitis was seen 
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in 14 of 16 mice from group A (p=0.5, FET) and 19 of 32 mice from groups B and 
C (p=0.03, FET). Hepatic lesions were seen in 8 of 16 dexamethasone-treated 
mice from group B and 25 of 31 mice from groups A and C. Mice in groups A and 
C were 4.2 times more likely to have hepatic lesions than mice in group B (95% 
CI: 1.1-15.7). Seven of 20 mice from mouse groups D, E, and G (euthanized 14 
and 28 DPI) had hepatic lesions compared to 5 of 15 mice from groups F and H 
(euthanized 42 and 59 DPI), and was not a statistically significant difference 
(p=0.6, FET). There was no statistically significant difference in hepatitis 
observed in mice treated with cyclophosphamide starting three days before 
infection (groups D and E) compared to mice that started treatment 28 DPI 
(group F). Hepatitis was seen in 9 of 10 mice from groups D and E and all 5 mice 
from group F (p=0.34, FET).    
Mild interstitial pneumonia (Figure 1C), characterized by increased 
numbers of lymphocytes, plasma cells and rare neutrophils expanding the 
pulmonary interstitium, was the most common lung lesion and was observed in 
18 of 23 young and 18 of 24 aged mice, from mice in groups A, B, and C. There 
was no statistically significant difference in the frequency of interstitial pneumonia 
between young and aged mice from groups A, B, and C (OR: 1.2, 95% CI: 0.3-
4.6). Interstitial pneumonia was observed in 13 of 16 dexamethasone-treated 
mice from group B compared to 23 of 32 mice from groups A and C this 
difference was not statistically significant (p=0.7, FET). Mouse age was an 
interaction term in the comparison of the frequency of interstitial pneumonia 
between dexamethasone-treated mice in group B. Interstitial pneumonia was 
 
 
60 
observed in all 8 young mice from group A (p=0.12) and 5 of 8 aged mice from 
group B (p=0.36). Interstitial pneumonia was seen in 9 of 15 mice from 
cyclophosphamide-treated mice in groups D, E, and F and nine mice from control 
mice in groups G and H, and was not a statistically significant difference between 
mouse groups (OR: 1.7, 95% CI: 0.4-6.6). Duration of infection was an 
interaction variable when comparing interstitial pneumonia between 
cyclophosphamide-treated groups D, E, and F. Six of 20 mice from groups D, E, 
and G (euthanized 14 and 28 DPI) had interstitial pneumonia (p=0.3, FET) 
compared to 3 of 15 mice from groups F and H (euthanized 42 and 59 DPI) 
(p=0.07, FET). Interstitial pneumonia was seen in 4 of 10 mice that received 
cyclophosphamide treatment three days before infection (groups D and E) and all 
5 mice from group F that received cyclophosphamide treatment 28 DPI, and this 
difference was not statistically significant difference (p=0.6, FET).  
Small foci of lymphocytic inflammation within the heart (Figure 1D), were 
observed in 2 young and 3 aged mice from groups A, B, and C. Myocarditis was 
not seen in any dexamethasone-treated mice from group B, which was not a 
significant difference in comparison to myocarditis in groups A and C (p=0.15, 
FET). Myocarditis was seen in 7 of 15 cyclophosphamide treated mice from 
groups D, E, and F and 5 of 20 control mice from groups G and H, a difference 
that was not statistically significant (OR: 2.3, 95% CI: 0.53-9.7). Duration of 
infection was an interaction variable when comparing myocarditis between 
groups D, E, F, G, and H. Seven of 20 mice from groups D, E, and G (euthanized 
14 and 28 DPI) had myocardial lesions (p=0.6, FET). However, myocarditis was 
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not seen in any mice from groups F and H (euthanized 42 and 59 DPI). 
Myocardial lesions were observed in 4 of 10 mice that began cyclophosphamide 
treatment three days before infection (groups D and E) compared to 3 of 5 mice 
from group F (euthanized 59 DPI), this difference was not statistically significant 
(p=0.1, FET).  
Lymphoid hyperplasia was the most commonly observed splenic lesion 
and was observed in 6 of 23 young and 6 of 24 aged mice from mouse groups A, 
B, and C. There was no statistically significant difference in splenic hyperplasia 
between mouse ages (OR: 0.94, 95% CI: 0.25-3.6). Splenic lymphoid 
hyperplasia was not observed in any dexamethasone-treated mice from group B, 
this was a statistically significant different compared to hyperplasia observed in 
mice from groups A and C (p=0.02, FET). Splenic lymphoid hyperplasia was 
seen in all 15 mice from cyclophosphamide treated groups D, E, and F and 18 of 
20 control mice from groups G and H. 
Interstitial nephritis, aggregates of lymphocytes and plasma cells 
expanding the interstitium. Nephritis was seen in 4 of 23 young and 8 of 24 aged 
mice from groups A and C and was a statistically significant difference between 
these groups (p=0.02, FET). Nephritis was not observed in any dexamethasone-
treated mouse from group B, which was a statistically significant difference 
compared to groups A and C (p=0.004). Nephritis was observed in 3 of 20 control 
mice from groups G and H, and was not seen in any mouse from 
cyclophosphamide-treated groups D, E, and F, this difference was not 
statistically significant (p=0.2, FET).  
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Figure 1: A-D) Histopathologic Lesions Associated with C. burnetii. 
A) Hepatitis, B) steroid hepatopathy, C) interstitial pneumonia, and D) 
myocarditis. 
 
 
63 
Bacterial Infection in Mouse Tissues   
Mean splenic and bone marrow bacterial GE values derived from the 
qPCR IS1111 assay for each mouse group are listed in Table 2. 
Table 2.  
Effect of Age and Chemically Induced Immunosuppression on C. burnetii  
Infection in Mouse Tissues. 
Mouse 
Group 
N 9 wks,  
N 9 mos 
Treatment  Euthanasia 
DPI 
Spleen  
GE* ± SD 
Bone 
Marrow  
GE* ± SD 
A 7, 8 None 14 25.6 ± 22.7 10.7 ± 30.4 
B 8, 8 DEX 42 1.3 ± 1.1 1.1 ± 0.25 
C 8, 8 None 42 1.0 ± 0.0 1.0 ± 0.0 
D 5, 0 CY -3 14 18.5 ± 21.7 1.4 ± 0.6 
E 5, 0 CY -3 28 1.1 ± 0.1 1.0 ± 0.0 
F 5, 0 CY 28 DPI 42 1.0 ± 0.0 1.0 ± 0.0 
G 10, 0 None 14, 28 13.5 ± 4.5 10.4 ± 6.0 
H 10, 0 None 59 0.2 ± 0.1 1.0  ± 0.0 
* GE: genome equivalents, values <5 were converted to a value of 1 for data 
analysis. 
N: number of mice in each group. 
CY: cyclophosphamide beginning three days before infection or 28 days after 
infection.  
DEX: dexamethasone 
DPI: days post inoculation. 
SD: standard deviation. 
 
There was no statistically significant difference in the mean bacterial GE 
values between young and aged mice from groups A, B, and C (F: 1.3, DF: 1, 
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p=0.3). There was a statistically significant difference in the mean splenic 
bacterial GE values between dexamethasone-treated mice from group B 
compared to groups A and C (F: 9.1, DF: 1, p=0.006). There was no statistically 
significant difference in the mean splenic bacterial GE value from 
cyclophosphamide-treated groups D, E, and F compared to control mice in 
groups G and H (F: 0.15, DF: 1, p=0.7). There was no statistically significant 
difference in mean splenic bacterial GE values from mice that started 
cyclophosphamide treatment three days before infection (groups D and E) 
compared to mice that started cyclophosphamide treatment 28 DPI group F (F: 
0.6, DF: 3, p=0.7). 
There was no statistical difference in the frequency of IFA positive splenic 
samples between mouse ages, mouse groups A, B, and C, (OR: 1.5, 95% CI: 
0.4-5.6). Additionally, no difference was observed in the frequency of positive IFA 
scores between dexamethasone-treated mice, in group B and mice in groups A 
and C (p=0.2, FET). Lastly, there was no difference in the frequency of IFA 
positive spleen samples between cyclophosphamide-treated mice in groups D, E, 
and F, and control mice in groups G and H (p=0.7, FET). 
 Mouse age had no effect on the amount of bacterial DNA detected in the 
tissues from mice in groups A, B, and C. There was no significant difference in 
the mean bone marrow bacterial GE values between young and aged mice from 
groups A, B, and C (F: 0.3, DF: 1, p=0.6). Treatment with dexamethasone had no 
significant effect on the amount of bacteria detected in the bone marrow of mice 
from group B. There was no statistically significant difference in mean bone 
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marrow GE values from mice in group B compared to groups A and C (F: 0.3, 
DF: 1, p=0.6). Cyclophosphamide treatment had no effect on the amount of 
bacterial DNA detected in the bone marrow of infected mice. There was no 
statistically significant difference in the mean GE value of the bone marrow from 
cyclophosphamide mice in groups D, E, and F compared to control mice in 
groups G and H (F: 2.2, DF: 1, p=0.2). Also, there was no statistically significant 
difference in mean bone marrow GE values from mice in groups D, E, and G 
(euthanized 14 and 28 DPI) compared to groups F and H (euthanized 42 and 59 
DPI) (F; 2.2, DF: 3, p=0.1). Mean bone marrow bacterial GE values from mice 
that started cyclophosphamide treatment three days before infection (groups D 
and E) were not significantly different from mice that began cyclophosphamide 
treatment 28 DPI (group F) (F: 2.5, DF: 1, p=0.1).    
Discussion 
 
There are several disease manifestations that have been observed in 
human Q fever including, flu-like symptoms, pneumonia, hepatitis, and 
endocarditis [25, 114]. It is unclear why certain pathologies develop after 
infection, but disease variability has been linked to host factors [69, 70]. Age and 
host immune status were examined in mice to determine if these factors 
influence C. burnetii infection.  
This study found that there was no exacerbation of histopathologic lesions 
or increase in the amount of bacterial DNA detected in mouse tissues between 9-
week-old and 9-month-old C57BL/6 mice after C. burnetii infection. A previous 
mouse study by Leone et al. determined a significant difference in C. burnetii 
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bacterial burden of the spleen of 14-month old mice compared to 1-month-old 
mice disease, and the authors suggested that disease was exacerbated in the 
aged mice [134]. It is possible that our study did not observe a significant 
difference in C. burnetii infection between 9-week and 9-month-old mice because 
a more extreme age difference was necessary. Additionally, due to the 
constraints of pilot studies it is possible that low power prevented a significant 
difference from being observed.  
 Treatment with dexamethasone did not exacerbate C. burnetii disease in 
mice. Further, there was no interaction between age and dexamethasone 
treatment and disease development. As stated previously, dexamethasone can 
decrease the functionality of Fc receptors on macrophages [131]. In this study 
dexamethasone treatment may have induced changes in the macrophage 
receptors disrupting the infectious process of the bacterium. Fewer infected cells 
ascribes to fewer histopathologic lesions observed in infected mice. Steroid 
hepatopathy was observed in all dexamethasone treated mice. This hepatic 
pathology was caused by the dexamethasone treatment as similar pathologies 
have been observed in animals receiving long-term steroid therapy [135]. 
Treatment with dexamethasone did not exacerbate bacterial infection of mouse 
tissues or histopathologic lesions in mice infected with C. burnetii. Although the 
dosage of dexamethasone was derived from a previous study, the dose received 
by the mice may not have down-regulated the cell - mediated immune response, 
as anticipated and chronic disease did not develop. No information is available 
about the interaction of dexamethasone and C. burnetii. Overall, more studies 
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are necessary to evaluate the effect of dexamethasone-induced 
immunosuppression on C. burnetii infection in mice.  
Cyclophosphamide did not significantly exacerbate C. burnetii disease in 
mice. However, grossly cyclophosphamide-treated mice had significantly less 
splenomegaly than untreated mice. Previous studies have determined that 
cyclophosphamide treatment preferentially depletes lymphocytes from lymphoid 
organs in mice [136]. Therefore, less incidence of splenomegaly could have been 
the result of cyclophosphamide induced lymphocytic depletion. As with the 
dexamethasone treatment, cyclophosphamide did not exacerbate C. burnetii 
disease in mice. While this dose has been used to induce lymphocyte depletion 
in mice, the interaction of C. burnetii and cyclophosphamide has not been 
previously evaluated. Therefore, studies need to be conducted on the efficacy of 
cyclophosphamide inducing immunosuppression in C. burnetii infected mice to 
determine if this treatment affects disease development. 
The duration of infection was an interaction term in the evaluation of 
splenomegaly and interstitial pneumonia among cyclophosphamide-treated and 
untreated mice. In both comparisons, there was significantly less splenomegaly 
and interstitial pneumonia seen in mice euthanized late in the infection (42 and 
59 DPI). However, there was no difference in the incidence of splenomegaly and 
interstitial pneumonia in mice euthanized early in the infection (14 and 28 DPI). 
Additionally, more bacterial DNA was detected in the spleen and bone marrow of 
infected mice early in the infection compared to mice that were euthanized later. 
Bacterial infection in mouse tissues was highest approximately two weeks after 
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infection after which point, the amount of bacterial DNA detected in the tissues 
and frequency of histopathologic lesions significantly decreased. These results 
demonstrated that bacterial dissemination induced tissue infection early in the 
infectious process leading to the development of histopathologic lesions. 
Significantly fewer bacteria were detected in infected tissues and fewer 
histopathologic lesions six weeks after infection due in part to resolution by the 
host immune response.  
  Histopathologic lesions observed in infected mice mimic lesions observed 
in human cases of Q fever specifically, interstitial pneumonia, hepatitis, and 
myocarditis [66]. Interstitial pneumonia and myocarditis were observed in all 
mouse groups and development of these lesions was unaffected by host age or 
chemical treatment. Therefore, age may not be an important factor in 
development of cardiac and lung pathologies in human Q fever.  
This study demonstrated that mouse age did not have a significant impact 
on C. burnetii infection. Additionally, treatment with dexamethasone and 
cyclophosphamide did not significantly exacerbate C. burnetii disease in mice. 
Overall, this study determined that these attributes are not risk factors for 
enhanced C. burnetii disease in mice as they are determined to be for humans.  
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CHAPTER 4: EVALUATION OF DOXYCYCLINE THERAPY IN TRE ATING 
 C. BURNETII  INFECTION IN MICE 
Introduction 
The intracellular bacterium Coxiella burnetii induces a spectrum of 
disorders in infected humans, ranging from subclinical to severe disease. In 
some untreated patients, infections can persist throughout life. Examples of 
chronic infections include cases of C. burnetii begin maintained for over 20 years 
in the bone marrow of infected humans and sequela such as endocarditis 
associated with long-term infections [120, 137]. The primary treatment for acute 
Q fever is a two-week course of doxycycline therapy [64]. In the majority of 
cases, this treatment clears infection; however, latent and chronic infections have 
been reported after doxycycline-treatment [120]. Chronic infections require long- 
term therapies to ensure the host maintains immunity and eventually clears the 
infection. Cases of chronic Q fever endocarditis require extensive antimicrobial 
therapy, with multi-drug therapies given for the life of the host [138]. Additionally, 
several cases of endocarditis have required valvular graft replacement [139]. 
There are many theories about why acute disease becomes chronic in 1-2% 
infected cases [64]. In order to prevent the conversion from acute to chronic 
disease, effective antimicrobial therapies must be given shortly after infection to 
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control and clear bacterial infection in the host. The objective of this study was to 
evaluate the effectiveness of doxycycline treatment on C. burnetii infected mice 
to provide a baseline assessment to which future antimicrobial trials could be 
compared.  
Doxycycline is a tetracycline derivative that is effective in treating gram-
positive and gram-negative aerobic and anaerobic pathogens and has been 
determined to be the best antimicrobial to treat C. burnetii infections [140, 141]. 
Doxycycline is bacteriostatic and works by penetrating the bacterial cell wall 
interfering with protein biosynthesis, primarily on the 70S ribosome [140]. 
Doxycycline also binds to the 30S ribosomal subunit preventing the binding of 
bacterial mRNA to tRNA and doxycycline inhibits mitochondrial protein synthesis 
[140]. Chronic Q fever is much more difficult to treat and adjunctive therapy with 
hydroxychloroquine is used as an alkalizing agent to disrupt the acidic 
environment of the parasitophorous vacuole [141]. The following experimental 
mouse infection study evaluates the effectiveness of doxycycline, administered in 
mouse drinking water, in preventing C. burnetii protein synthesis and subsequent 
infection.  
Materials and Methods 
Animals 
 
Thirty-five C57BL/6 (8 week-old female) mice were purchased from 
Charles River Laboratories (Wilmington, MA, USA). Mice were housed at the 
Colorado State University Infectious Disease Research Center in ventilated 
cages under HEPA-filtered barrier conditions. Water and food were provided ad 
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libitum. Animal care and use procedures were carried out in accordance with 
university policies [116]. Clinical signs and water consumption were recorded 
daily, and mouse body weights were recorded twice weekly. 
Microorganism 
 
The Nine Mile Phase I strain (RSA493) of C. burnetii was originally 
obtained from the American Type Culture Collection (Manassas VA, USA).  
Laboratory stocks of the bacteria were prepared from the spleens of infected A/J 
mice, stored in aliquots at -80oC and titrated by intranasal inoculation in C57BL/6 
mice (see Chapter 2).  
Mouse Experimental Infections 
 
Mice were anesthetized prior to inoculation using an IP injection of a 
mixture of ketamine and xylazine (100 and 10 mg/kg respectively). Mice were 
inoculated IN with 3000 ID50 of C. burnetii diluted with phosphate buffered saline 
(PBS) described in Chapter 2. Mouse treatment groups are listed in Table 1; 
Groups A and B were treated with doxycycline seven days after infection; Group 
C began doxycycline-treatment 28 days post infection (DPI). Mice in groups D, E, 
and F (previously described in Experiment 2, Chapter 2) served as infected, non-
treated controls, five mice from group D were euthanized 14 DPI and five were 
euthanized 28 DPI. 
Doxycycline hyclate powder (CSU Veterinary Teaching Hospital 
pharmacy) was added to mouse drinking water at a final dose of 200 ug/ml as 
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previously described [142]. Medicated drinking water was changed every other 
day until the mice were euthanized   
Table 1.  
Doxycycline and C. burnetii Infection Study Design. 
Group Number of Mice Days of Doxycycline Treatment Day of Euthanasia 
A 5 7 – 14 14 DPI 
B 5 7 – 28 28 DPI 
C 5 28 – 42 42 DPI 
D 5 None 14 DPI 
E 5 None 28 DPI 
F 10 None 59 DPI 
DPI: days post inoculation. 
Blood samples were obtained under ketamine-xylazine anesthesia by 
intracardiac puncture, immediately prior to euthanasia. Necropsies were 
performed and samples of the spleen, liver, lungs, heart, and kidney were 
collected in 10% neutral-buffered formalin. Tissue sections were embedded in 
paraffin, and sections stained with hematoxylin and eosin for microscopic review, 
Dr. Colleen Duncan conducted all histopathologic evaluations. Splenic 
enlargement was graded on a scale from 0-5; with 0 indicating a smaller than 
average spleen size, 1 an average sized spleen, and 5 a grossly enlarged spleen 
(approximately ≥ 5 times larger than average). One half of each spleen was 
stored frozen at -80°C for DNA extraction. Bone marro w washes were performed 
by injecting 0.5 ml of PBS into the broken femur cavity, and stored at -80°C.  
Assays for Detection of C. burnetii 
 
Indirect Immunofluorescence Assay (IFA).  Approximately 10 milligrams of 
spleen were used to prepare splenic squash mounts.  Slides were fixed in 70% 
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acetone for at least 12 hours, then immunostained and evaluated as described in 
Chapter 2.  Fluorescence signal was subjectively graded on a scale from 0-3, 
with 0 designated as negative fluorescence, and 3 designated as a strong signal 
of fluorescence.   
Polymerase Chain Reaction (PCR).  Bacterial DNA extraction was performed 
on mouse splenic and bone marrow tissue samples, quantitative PCR assays 
were conducted to detect the C. burnetii insertion sequence IS1111 gene as 
described in Chapter 2.   
Statistical Analyses 
 
 Mean genome equivalent (GE) values from qPCR assays of spleen and 
bone marrow were compared between doxycycline-treated and non-treated, 
infected control mice using analysis of variance (ANOVA). GE values less than 5 
were converted to a value of 1 for analysis. Mouse samples that fell below the 
detectable qPCR threshold value of 1000 were converted to missing values in 
SPSS to ensure accuracy when statistically evaluating quantitative data. 
Differences between doxycycline treatment groups were determined using the 
Tukey’s post-hoc test. The Pearson’s Chi-square test and odds ratios, when 
appropriate, were used to compare frequencies of categorical data. The Fischer’s 
exact test (FET) was used for categorical frequencies less than five. For all 
statistical tests, a p-value ≤0.05 was considered statistically significant. All 
statistical analyses were performed using SPSS software (IBM, version 19, 
Somers, NY). 
 
 
76 
Results 
Clinical Disease and Gross Pathology 
 
 Morbidity was not observed in any of the mice over the 42-day infection 
time course. One infected control mouse died shortly after inoculation; a 
necropsy was not performed. Splenomegaly was the only significant gross lesion 
observed during necropsy; this was seen in two doxycycline-treated mice from 
mouse groups A and B and in 15 of 20 mice in groups D, E, and F. Mice that 
were not treated with doxycycline were 24 times more likely to have enlarged 
spleens than mice in groups A, B, and C (95% CI: 4.6, 129.8). There was not a 
significant difference in splenomegaly between mice that started doxycycline 
treatment seven days after infection (groups A and B) compared to those that 
started treatment 28 DPI (group C) (p=0.5, FET). 
Histopathology 
 
 Hepatic lesions were seen in 30 of 34 infected mice and were 
characterized as mild to moderate inflammation, lymphohistiocytic in nature with 
many small microgranulomas randomly distributed throughout the hepatic 
parenchyma. Hepatitis was seen in 13 of 15 doxycycline treated mice from the 
mice groups A, B, and C, and 17 of 20 control mice from groups D, E, and F, 
which was not a significant difference (p=1.0, FET). Additionally, hepatitis was 
observed in 8 of 10 mice from groups A and B (euthanized 14 and 28 DPI) 
compared to 5 mice from group C (euthanized 42 DPI), this difference also was 
not significant (p=0.5, FET).  
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 Mild, lymphoplasmacytic, interstitial pneumonia was the most commonly 
observed lung lesion. Interstitial pneumonia was observed in 4 of 15 doxycycline-
treated from groups A, B, and C and 9 of 20 control mice from groups D, E, and 
F, which was not a significant difference (OR: 2.5, 95% CI: 0.6-10.7). Duration of 
infection was evaluated as an interaction term in the comparison of interstitial 
pneumonia and doxycycline treatment. Four mice from groups A, B, D, and E 
(euthanized 14 and 28 DPI) had pulmonary lesions (p=0.06, FET), and 
pneumonia was not observed in any mice from groups C and F (euthanized 42 
and 59 DPI) (p=1.0, FET). There was no significant difference in the incidence of 
interstitial pneumonia between mice that received doxycycline-treatment seven 
DPI (groups A and B) compared to group C mice that started treatment 28 DPI 
(p=0.2, FET). 
 In addition to the major histopathologic lesions observed in the liver and 
lungs, lesions were seen in the spleen, heart, and kidney of infected mice. 
Splenic lymphoid hyperplasia was seen in 5 doxycycline-treated mice from group 
C, and 18 control mice from groups D, E, and F; this was a statistically significant 
difference between mouse groups (p=0.00, FET). Mild lymphocytic myocarditis 
was observed in one doxycycline treated mouse from group A and 5 control mice 
from groups E and F; this difference was not significant (p=0.2, FET). 
Lymphoplasmacytic interstitial nephritis was seen in four doxycycline-treated 
mice from groups A and B, and three control mice from groups D, E, and F, this 
difference was not statistically significant (p=0.7, FET). Interstitial nephritis was 
not seen in any dexamethasone mice that began treatment 28 DPI (group C) 
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compared to four mice that began doxycycline treatment 7 DPI (groups A and B) 
this difference was not statistically significant (p=0.2, FET).  
Bacterial Burden in Tissues 
Mean splenic and bone marrow bacterial GE values derived from the 
qPCR IS1111 assay for each mouse group are listed in Table 2.   
Table 2 . 
Detection of C. burnetii DNA in Tissues after Treatment with Doxycycline. 
Group  Number 
of Mice 
Treatment, 
Start Day 
Day of 
Euthanasia  
Spleen  
GE* ± SD 
Bone 
Marrow 
GE* ± SD 
A 5 Doxy, 7 14 7.7 ± 4.1 3.1 ± 4.2 
B 5 Doxy, 7 28 1.0 ± 0.0 1.0 ± 0.0 
C 5 Doxy, 28 42 0 ± 0 1.0 ± 0.0 
D 5 None 14 21.2 ± 14.4  10.5 ± 12.2  
E 5 None 28 2.3 ± 2.9 1.0 ± 0.0 
F 10 None 59 1.1 ± 0.2 1.0 ± 0.0 
* GE: genome equivalent, values <5 were changed to a value of 1 for statistical 
analysis.  
Doxy: doxycycline treatment added to mouse drinking water. 
SD: standard deviation. 
 
Doxycycline-treated mice from groups A, B, and C and untreated mice 
from groups D, E, and F had similar quantities of bacterial DNA in their splenic 
tissue as determined by qPCR (F: 2.2, DF: 1, p=0.1). There was no statistically 
significant difference in the mean splenic GE values for mice in groups A, B, D, 
and E (euthanized 14 and 28 DPI) compared to mice in groups C and F 
(euthanized 42 and 59 DPI) (F: 1.1, DF: 1, p=0.3).  
The amount of bacterial DNA detected in the bone marrow of doxycycline-
treated mice in groups A, B, and C compared to control mice in groups D, E, and 
F was similar (F: 1.8, DF: 1, p=0.2). There was no difference in the amount of 
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bacterial DNA detected in the bone marrow of mice from euthanized 14 and 28 
DPI (groups A, B, D, and E) compared to mice euthanized 42 and 59 DPI 
(groups C and F) (F: 2.3, DF: 1, p=0.1). Also, there was no difference in mean 
bone marrow GE values between doxycycline treated mice in groups A and B 
compared to group C (F: 0.4, DF: 1, p=0.5).  
There was a significant difference in the quantity of splenic bacteria as 
determined by IFA analysis between doxycycline-treated mice in groups A, B, 
and C and non-treated groups D, E, and F. Eight mice from doxycycline treated 
mice in groups A, B, and C had IFA positive splenic samples compared to 3 
control mice from groups D and F (p=0.03, FET). Seven mice from group A and 
B had positive IFA samples compared to one mouse from group C; this 
difference was not significant (p=0.1, FET). 
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Discussion 
 
 Doxycycline therapy is the most commonly prescribed antibiotic to treat 
human Q fever [64]. Results of this study suggested that doxycycline treatment 
did not significantly affect C. burnetii disease development in mice. Mice received 
doxycycline treatment beginning seven or 28 days after infection and there was 
no difference in the ability of doxycycline to resolve bacterial infection at either 
treatment start day. The incidence of splenomegaly and splenic hyperplasia were 
significantly decreased in doxycycline treated mice compared to infected control 
mice. These results suggested that doxycycline was effective in preventing C. 
burnetii from inducing an inflammatory reaction in the spleen.  
 As was observed in the previous chapters, detection of bacterial DNA in 
mouse tissues and incidence of histopathologic lesions were highest early in the 
course of infection and significantly decreased 14 days after infection. Duration of 
infection was an interaction variable in the evaluation of histopathologic lesions 
and doxycycline treatment. Splenomegaly was not seen in doxycycline-treated 
mice later in the infection (42 DPI) compared to mice euthanized early in the 
infection (14 and 28 DPI). In doxycycline-treated mice, cardiac and pulmonary 
lesions were more severe early in the course of infection, and these lesions were 
not seen in mice euthanized 42 days after infection. We did not have a group of 
untreated mice euthanized at day 42, but the untreated mice euthanized at day 
59 showed a similar resolution of lesions, making it difficult to ascertain the 
efficacy of doxycycline treatment.   
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 The frequency of hepatitis and nephritis were similar between doxycycline-
treated mice and infected controls. Similar frequencies of nephritis were seen in 
both doxycycline and infected control mice early in the infection with complete 
resolution of by 42 and 59 DPI. These results suggest that this non-specific, 
inflammatory lesion completely resolves late in the infection with or without 
doxycycline treatment. Hepatitis was still evident in doxycycline-treated and 
infected controls late in the infection. These findings suggest that the liver 
becomes chronically infected in mice, and doxycycline treatment as dosed in this 
study was not sufficient to clear infection by 42 DPI.  
These findings indicate that at the dosage of doxycycline utilized in this 
experiment was effective in mitigating splenomegaly and splenic histopathology, 
but did not appear to have high efficacy in accelerating resolution of 
histopathologic lesions induced by C. burnetii infection in mice
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Chapter 5: CONCLUSIONS FROM C. BURNETII MOUSE INFECTION 
STUDIES 
 
Results from these mouse experimental inoculation studies demonstrate 
that the C57BL/6 mouse strain develops infection when intranasally inoculated 
with the Coxiella burnetii Nine Mile phase I strain. Previous studies have 
concluded that C57BL/6 mice are resistant to C. burnetii infection [112]. 
However, the mouse infection studies prove that C57BL/6 mice develop similar 
histopathologic disease observed in human Q fever. Humans develop disease 
through inhalation of infectious aerosols; our experiments mimic the natural route 
of exposure by infecting mice intranasally. Hepatitis and interstitial pneumonia 
were the most commonly observed histopathologic lesions in infected mice, and 
are the two primary disease manifestations observed in acute human disease 
[64]. Chronic Q fever is commonly associated with cardiac lesions, similarly, 
myocarditis was observed in intranasally infected mice, and has not been 
previously described with this inoculation route. Additionally, splenic lymphoid 
hyperplasia, interstitial nephritis, and myocarditis were also observed in infected 
mice. Hepatic lesions and splenic lymphoid hyperplasia were observed two 
months after infection and demonstrate that these tissues may develop chronic 
infection. 
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Development of human disease has been ascribed to many factors 
including host age and immune competency. Human disease is almost 
exclusively described in people over 15 years of age, and is most commonly 
seen in people over 50 years [70, 71]. However, these mouse experiments 
demonstrate that age did not exacerbate C. burnetii disease in mice.  
 Dexamethasone and cyclophosphamide drugs were given to mice to 
induce immunosuppression. The doses received by infected mice [128, 143, 144] 
did not induce exacerbate disease in mice, and more information is needed to 
understand the relationship of dexamethasone and cyclophosphamide with C. 
burnetii. Doxycycline treatment was evaluated in resolution of C. burnetii infection 
in infected mice. Treatment with doxycycline was effective in decreasing the 
incidence of splenic infection in mice. However, it was not effective in significantly 
decreasing the amount of bacterial DNA in infected tissues or development of 
histopathologic lesions. Our results demonstrated that the dose of doxycycline 
used was marginally effective in treating C. burnetii infection in mice and further 
studies need to evaluate the efficacy of higher doses.  
 Due to the intracellular nature of this bacterium, animal models are 
essential in the development of vaccine and drug therapies and uncovering 
pathogenic mechanisms of C. burnetii. These experimental infection studies 
found that intranasal infection induces histopathologic disease and tissue 
infections in C57BL/6 mice, and more severe disease is seen in aged mice. The 
liver and bone marrow of infected mice becomes chronically infected with 
bacterial detection and histopathologic lesions evident two months after infection, 
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and cannot be effectively treated with doxycycline. In conclusion, these studies 
reveal important findings about C. burnetii essential for understanding bacterial 
pathogenesis in the mouse host. 
Experimental Research Constraints 
 
 Determining the number of animals in an infection study is surrounded 
with ethical concerns and costs. These experimental infection studies were 
conducted as pilot studies in an attempt to understand C. burnetii infection in 
mice. Therefore, low numbers of mice were maintained for each study. 
Unfortunately, the low power of these treatment groups may have prevented the 
observation of significant effects.  
Smaller pilot immunosuppression and treatment studies should have been 
performed before infection studies in order to determine the appropriate dose for 
C57BL/6 mice. This may have helped solidify results about the effect of 
immunosuppression and doxycycline treatment on C. burnetii infections in mice.   
Future Directions 
 
 The effect of chemically induced immunosuppression in C. burnetii 
infection in mice needs to be assessed. Experimental inoculation studies 
evaluating immunosuppression before infection will reveal differences in disease 
development compared to infected control mice. Also, immunosuppression after 
infection should be evaluated to determine if infection would recrudesce in 
tissues where lesions have resolved.    
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